Safety depends less on the molecule than on the category it sits in. What is documented for each, what is still unknown, and where the real risks concentrate.
Written bySebastian Hunter, Founder and EditorI'm a 42-year-old senior advisor and distance runner who came to peptides as a sceptic. I'm not a doctor: I read the research, run my own experiment and keep honest notes. Read full bio
·
The short version
Peptide safety is not one answer. Legal supplements, prescription medicines and research chemicals carry different risk profiles and very different quality controls. Start with which category a product sits in, because that decides what is known about it.
Safety claims must name the specific peptide and its legal class.
Research chemicals lack the human safety packages of approved drugs.
Purity and mislabeling are real consumer risks in grey markets.
“Are peptides safe?” is at least four questions. Which one you are asking depends on what is in front of you:
a tub of collagen powder
a face serum
a prescription your doctor wrote
a vial that arrived in a padded envelope labeled for laboratory research
Those four share a chemical description (short chains of amino acids) and almost nothing else. They sit in different
legal categories, carry different evidence, and fail in different ways. This page says, as precisely as my sources
allow, what is documented, what is only asserted, and what nobody knows.
The short answer
Collagen peptides and topical cosmetic peptides are, on the available evidence, low-risk consumer products. Their main
problem is that they may not do much. FDA-approved prescription peptide medicines have real effects and real side
effects, which is why a clinician is involved.
The “research use only” vials are what most people arrive asking about. For them, nobody has done the studies, so
nobody can tell you.
The category decides nearly everything
Before any question about a molecule, ask what the thing is, legally. The answer determines who checked it, what may be
claimed for it, and what happens if it is wrong.
Collagen & skinReal human trials behind them, and you can buy them today. Sold as supplements or cosmetics.Collagen peptides · Copper peptides (GHK-Cu) · Topical signal peptides
How you'd get it
Buy it in a shop or online today. No prescription, no grey market.
Where it stands legally
Sold legally as supplements (collagen) or cosmetics (topical peptides). Neither category is FDA-approved before sale - that is normal and it is not a scandal, but it does mean the burden of evidence sits with the manufacturer.
Prescription / GLP-1The most studied peptides there are. Approved medicines, large human trials, prescription only.Semaglutide · Tirzepatide
How you'd get it
Through a licensed clinician who assesses whether it is appropriate for you.
Where it stands legally
FDA-approved medicines that have been through clinical trials. Legal, well-studied, and prescription-only for good reason - they have real effects and real side effects.
Research peptidesThe frontier. Striking early findings, mostly in animals, and not approved for human use.BPC-157 · TB-500 · CJC-1295 · Ipamorelin
How you'd get it
Sold online by "research chemical" vendors, labelled not for human use.
Where it stands legally
Not approved for human use in the US. The "research use only" label is the legal basis on which vendors sell at all - it is not a wink, it is the thing that keeps the sale lawful. Purity and contents are not verified by any regulator.
Open one to see how it's sold, and where it stands legally.
The legal spine: intended use
The Federal Food, Drug, and Cosmetic Act sorts products by intended use, not by molecule:
Cosmetic (21 U.S.C. §321(i)): an article “intended to be rubbed, poured, sprinkled, or sprayed on, introduced
into, or otherwise applied to the human body… for cleansing, beautifying, promoting attractiveness, or altering the
appearance.”
Drug (§321(g)(1)(B)–(C)): an article “intended for use in the diagnosis, cure, mitigation, treatment, or
prevention of disease,” or “intended to affect the structure or any function of the body.”
So the same tripeptide can be a cosmetic or a drug, depending on what it is sold to do. The chemistry does not change;
the intent does.
A dietary supplement is defined at §321(ff)(2)(A)(i) as something intended for ingestion. An injectable peptide
therefore cannot lawfully be marketed as a dietary supplement, whatever the ingredient. No peptide-specific ruling is
needed to reach that.
Dietary supplements
US legal status - Dietary supplement
Regulated as a dietary supplement in the US. Supplements are not FDA-approved; manufacturers are responsible for their own safety and labelling, and the FDA acts only after a problem surfaces.
FDA’s consumer Q&A on dietary supplements sets out the position. Under DSHEA the agency has no authority to approve
dietary supplements before they are marketed, and is generally limited to postmarket enforcement. Structure/function
claims are not approved by FDA and need no FDA evaluation before use. They must carry a disclaimer that the product is
not intended to “diagnose, treat, cure, or prevent any disease”. In FDA’s words, only a drug can legally make such a
claim.
The firm, not the agency, must hold the substantiation. FDA and the FTC share oversight: FTC regulates the advertising,
and FDA is generally responsible for safety, quality and labeling.
None of that makes supplements dangerous. It makes them unverified before sale.
Cosmetics
US legal status - Cosmetic
Regulated as a cosmetic in the US. Cosmetics are not FDA-approved before sale, and may only make appearance claims - a product claiming to change the structure or function of skin is making a drug claim.
US legal status - FDA-approved · prescription only
An FDA-approved prescription medicine. It has been through clinical trials for its approved use, and legally requires a prescription from a licensed clinician.
This category has the most evidence and so the longest list of documented side effects. Approved medicines went through
trials designed to find harms. A short side-effect list elsewhere is no reassurance; it usually means nobody looked.
“Research use only”
US legal status - Research use only
Sold for laboratory research use only. Not approved by the FDA for human use, and cannot be lawfully marketed as a supplement or a medicine. Products sold this way are not made to pharmaceutical quality standards, and their contents are not verified by anyone.
This is where the risk concentrates.
“Research use only” is not a legal shield
The most useful primary document I found is an FDA warning letter. On 10 December 2024, FDA wrote to Summit Research
Peptides:
“Despite statements on your product labeling marketing your products as ‘RESEARCH USE ONLY’ and ‘INTENDED AS A RESEARCH CHEMICAL ONLY,’ evidence obtained from your websites establish that your products are intended to be drugs for human use. Your products are drugs as defined by section 201(g)(1) of the FD&C Act…”
The products at issue included semaglutide, retatrutide, cagrilintide, tirzepatide and mazdutide. The evidence FDA
relied on was the seller’s own websites and social media.
The GLP-1 and compounding picture
This is the part of the page most likely to be out of date by the time you read it, so every claim carries a date.
The compounding window closed:
FDA determined the semaglutide injection shortage resolved on 21 February 2025.
The district court denied compounders’ preliminary injunctions in Outsourcing Facilities Association v. FDA
(5 March 2025 for tirzepatide; 24 April 2025 for semaglutide).
503A enforcement discretion then ended, and the 503B windows ran to 19 March and 22 May 2025.
On 30 April 2026, FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list. It found
no clinical need for outsourcing facilities to compound them from bulk substances. Comments closed 29 June 2026, and
I could not locate a final determination as of 15 July 2026.
Retatrutide and cagrilintide, per FDA, cannot be used in compounding under federal law at all. They are not
components of approved drugs and have not been found safe and effective for any condition.
The harm signal is documented. As of 31 May 2026, FDA had received 990 adverse event reports associated with
compounded semaglutide and more than 730 associated with compounded tirzepatide. FDA itself calls these likely
underreported, because state-licensed pharmacies that are not outsourcing facilities are not required to report at all.
FDA separately reports adverse events, some requiring hospitalization, from dosing errors. Patients measured and
self-administered incorrect doses, and health professionals miscalculated them. FDA also reports counterfeit Ozempic,
product labeled as compounded by pharmacies that do not exist or did not make it, and shipments arriving warm or
inadequately iced.
On the “research use only” trade specifically, FDA has warned companies selling unapproved semaglutide, tirzepatide or
retatrutide. Their products were falsely labeled “for research purposes” or “not for human consumption” but sold to
consumers for human use, with dosing instructions. FDA urges consumers not to buy them, calling them “of unknown quality and may be harmful.”
One secondary source is often miscited. A January 2026 commentary from the law firm Health Law Alliance says two
things. First, in September 2025 FDA “issued over 50 Warning Letters” to companies marketing compounded GLP-1s as
generic versions or making comparative claims to the approved products. Second, FDA separately “issued a series of
letters regarding mostly peptides being sold as ‘research use only’ (RUO) where the advertising indicated the product
was intended for human use.” That series names BPC-157, SARMs, semaglutide, tirzepatide and retatrutide. Two caveats apply:
It is a law firm’s blog, retrospective and single-authored, not FDA’s own database.
The two actions are distinct. No count attaches to the RUO letters, and they are not stated to be inside the 50-plus.
If you have seen “FDA sent 50+ warning letters about research peptides,” that sentence fuses two different things.
The compounding question, using the case I can document
BPC-157 is the clearest worked example, because there is a live regulatory record.
An archived FDA page (snapshot 21 April 2026) shows a row reading verbatim “BPC-157 | 503A | September 29, 2023”.
It sits in a column headed “Date added to category 2”, so that is the date BPC-157 entered category 2. Category 2 is the
interim-policy bucket FDA uses for nominated bulk drug substances where it “identified potential significant safety
risks.”
On the current version of that page, BPC-157 is no longer in the category 2 table at all. It sits in a separate
table headed “Bulk drug substances nominated but withdrawn.” FDA defines these as substances “previously in category 2
of the interim policies [that] were withdrawn by the nominators”. That table also lists AOD-9604, CJC-1295, epitalon,
GHK-Cu, melanotan II, semax and others. FDA kept its safety language for each. Against BPC-157 that language reads:
“Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization. FDA has identified no, or only limited, safety-related information for the proposed routes of administration…”
That is the most useful safety sentence on this page, and it is FDA’s. Withdrawal by a nominator is not an FDA safety
clearance. You cannot infer from that page that BPC-157 currently carries the category 2 enforcement posture. The word
“enforcement” does not appear on it once. The enforcement-discretion language people quote comes from a separate
interim policy guidance, which I did not verify this pass and do not quote.
Separately, FDA’s briefing document for the 23–24 July 2026 Pharmacy Compounding Advisory Committee meeting says:
“there is no applicable United States Pharmacopeia (USP) or National Formulary (NF) drug substance monograph for BPC-157 (free base) or its acetate form, and neither is a component of an FDA-approved drug.”
Under FD&C Act §503A, a bulk substance may be compounded only if it meets one of three conditions:
it complies with an applicable USP/NF monograph
it is a component of an approved drug
it is on FDA’s 503A Bulks List
The briefing document does not itself recite this framework. BPC-157 satisfies none of the three, and FDA’s staff proposed not
adding it to the list, so it is not presently eligible for lawful 503A compounding.
That document never mentions “category 2”, so it cannot settle what the category 2 removal means. The missing monograph
is background, not FDA’s stated basis. FDA’s proposal rests on:
inadequate physicochemical characterization
inconsistent naming conventions
lack of safety and immunogenicity data
insufficient evidence of effectiveness for ulcerative colitis
the availability of approved drugs for that condition
The risks that are actually documented
Product quality
FDA’s hazard language above names the problems: peptide-related impurities, API characterization, immunogenicity. Those
impurities are structurally similar to the peptide itself, which makes them hard to detect without serious analytics.
No regulator is running those analytics on grey-market product.
The peptides themselves are defined molecules; the question is whether a given product matches its label. A third-party
certificate of analysis can confirm one batch’s identity and purity. I could not find an independent survey of how
often research-use products match their labels, and no regulator checks them.
Sterility and reconstitution
A lyophilized powder is not a sterile injectable until someone makes it one, correctly. Nothing in my sources
quantifies how often that goes wrong, so I give no number. The failure modes are physical: a contaminated stopper, a
reused needle, a non-sterile surface, a vial kept for weeks after being punctured.
The unit system is a trap. The U-number on an insulin syringe is units per milliliter. That is my derivation from
the labels below, not a rule any one of them states. U-100 means 100 units/mL, so one unit is 0.01 mL.
The Humulin R label states “100 UNITS PER ML (U-100)” and that “a U-100 insulin syringe should always be used.”
U-40 veterinary insulin (Vetsulin, 40 iU/mL) carries the all-caps warning that “USE OF A SYRINGE OTHER THAN A U-40
SYRINGE WILL RESULT IN INCORRECT DOSING.”
BD’s U-500 syringe holds up to 250 units in a 0.5 mL barrel. That is 500 units/mL, as the rule predicts, though that
last step is mine and not BD’s.
There is no such thing as a “U-50” syringe. A Minnesota Hospital Association patient-safety sheet says it directly:
“All insulin syringes are U-100 syringes-available in 30-unit, 50-unit and 100-unit sizes.” Fifty-unit is a barrel
capacity, not a calibration. Even the one commercial page I found promoting “U-50” as a category defines it as “100
units per ml in a 0.5 ml barrel”, which refutes itself.
One more piece of arithmetic is often stated wrongly: the number of doses in a vial does not depend on how much water
you add. Doses per vial is peptide mass divided by dose. Diluent volume changes only the volume you draw and how
readable that volume is on the barrel. Any source implying “add more water, get more doses” is wrong.
The diluent is not inert
Bacteriostatic water is sterile water plus a preservative, and the preservative is benzyl alcohol. The Pfizer product
information specifies “0.9% (9 mg/mL) or 1.1% (11 mg/mL) of benzyl alcohol”. So the 0.9% figure repeated across the
internet is common but not universal, and reading your own label matters.
That label’s benzyl alcohol note covers 0.9% preparations. Experimental studies “in several animal species have
indicated that an estimated intravenous dose up to 30 mL may be safely given to an adult without toxic effects.” It adds that roughly 9 mL in a 6 kg infant is potentially capable of producing blood pressure changes.
The adult ceiling is an animal-derived estimate, not a human trial finding.
The unknowns, which are the largest category
Limited human data
Small or uncontrolled human studies. Too little to settle the question either way. For BPC-157 - the most-discussed research peptide - the evidence base is overwhelmingly rodent: of 222 PubMed records, 156 are indexed to animals and none to a clinical-trial or randomized-controlled-trial publication type. The published human experience FDA could inventory is five short exploratory studies in roughly 80 people, one of which was a placebo-controlled trial that exists only as a meeting abstract and was null on its own numbers. FDA states it identified no, or only limited, safety-related information for the proposed routes of administration.
BPC-157 is the worked case. Human data are not absent, only very thin, and one piece of them is worse news than absence
would be.
FDA’s briefing document inventories the complete published human experience with BPC-157 as five studies, roughly 80
people in total:
A phase 1 rectal enema study in healthy volunteers, with 32 randomized and 24 dosed.
One randomized placebo-controlled trial.
A retrospective chart review of 17 people with knee pain.
A single-arm study of 12 people with interstitial cystitis.
A two-patient intravenous report.
No serious adverse events were reported across them. But the studies were short, tiny and mostly unblinded, and safety
monitoring was largely unclear. Studies of that size cannot find an uncommon harm, so “no serious adverse events” is
close to uninformative here.
The randomized trial is the one that matters, and nobody quotes it. It compared an 80 mg enema against placebo for two
weeks in 53 people with ulcerative colitis. It exists only as a meeting abstract, and it did not show a benefit.
Mean disease-activity-index change was −3.2 (95% CI −5.58 to −0.82) on BPC-157 versus −1.6 (95% CI −3.86 to 0.67) on
placebo. The between-group difference was 1.6 (95% CI −4.84 to 1.62), an interval straddling zero. So the human record
holds exactly one controlled trial, never published beyond an abstract, and on its own numbers it was null.
None of this is indexed as a trial. A PubMed query for ("BPC 157" OR "BPC-157") AND clinical trial[pt], run on
15 July 2026, returns zero records, which a meeting abstract would not appear in regardless. Of the 222 indexed
records, 175 (79%) list Sikiric P or Seiwerth S of the University of Zagreb, and 47 exist without either. The
literature is concentrated rather than closed, and has little independent replication.
You cannot derive a safe dose, an interval or a duration from this record. It has five short exploratory studies and
one null, abstract-only trial. FDA found no, or only limited, safety information for the routes people actually use.
Red flags when sourcing
My sources do not support a scored checklist. This is my editorial judgment applied to the regulatory facts above, not
a validated instrument:
“Research use only” alongside human dosing advice. The disclaimer and the dosing chart cannot both be sincere.
FDA’s Summit letter is exactly this pattern.
A certificate of analysis you cannot trace. A PDF with no lab name, no date, no batch and no method is a graphic
design asset.
Purity claims without a named analytical method. “99% purity” means nothing without knowing what was measured
and how. FDA’s stated concern is impurities structurally similar to the peptide itself.
Any human indication in the marketing copy. Under §321(g)(1) that is a drug claim, and a seller making one is
telling you they are not a research supplier.
A consumer sales channel wearing a lab coat - subscription boxes, bulk discounts, “starter stacks.”
One common name covering several salts or derivatives. FDA flagged inconsistent naming and characterization as
unresolved for BPC-157. Even the animal literature may not describe what arrives.
“It’s a supplement.” If it is injectable, it is not one. A dietary supplement must be intended for ingestion.
When to see a doctor
This is my judgment, not a cited finding: see a doctor before you start, not after.
A clinician can tell you whether an FDA-approved medicine exists for what you are trying to treat. Often one does, and
the person selling vials has no reason to mention it.
Afterward, seek care promptly if you feel unwell following an injection, if an injection site becomes red, swollen,
warm or painful, or if you develop a fever. Bring the actual vial and label. “A peptide from the internet” is not a
history a clinician can work with; a product name, a lot number and a concentration is.
If you take a prescription medicine, particularly anything affecting blood glucose, blood pressure or clotting, the
literature cannot answer the interaction question, because the studies do not exist. Ask a clinician rather
than guess.
What I don’t know, in one place
Whether unapproved peptides are safe over months or years in humans. No data - not weak data, none.
What is actually in grey-market vials. No independent assay data was located.
Whether the July 2026 advisory committee changes BPC-157’s compounding status. Unresolved at publication.
How often reconstitution errors cause harm. Unmeasured, as far as my sources go.
How far FDA’s warning-letter activity extends. I verified one letter, and decline to extrapolate from it.
Common questions
Are peptides safe?
There is no single answer, because "peptides" is not one thing. A collagen supplement, a topical copper peptide cosmetic, an FDA-approved prescription peptide drug and a vial sold online for research use only are four legal categories with four evidence bases. For most research-use-only peptides, nobody knows, because the human safety studies have not been done.
Does a "research use only" label make a peptide legal to buy and inject?
No. Under the Federal Food, Drug, and Cosmetic Act a product is a drug based on its intended use, not on the words printed on the vial. In a December 2024 warning letter to one peptide seller, FDA wrote that the products were intended to be drugs for human use. Its evidence was the company's websites, despite research-use-only labeling. The label is a marketing convention, not a legal shield.
What are the biggest documented risks with grey-market peptides?
FDA has stated that compounded drugs containing BPC-157 may pose a risk for immunogenicity for certain routes of administration. It said they may also have complexities regarding peptide-related impurities and active ingredient characterization. FDA identified no or only limited safety information for the proposed routes. In plain terms: no regulator verifies what is in the vial, and the published human safety record fits in a paragraph. FDA's own 2026 review counts the entire published human experience with BPC-157 as five studies in roughly 80 people, all short, small and mostly exploratory. No serious adverse events were reported, but studies that size and length cannot find much.
Can a reconstitution mistake actually hurt me?
It can produce a dose that is a multiple of what you intended. The most common trap is confusing syringe capacity with syringe calibration: a 50-unit insulin syringe is not a "U-50" syringe. A Minnesota Hospital Association patient-safety sheet states that all insulin syringes are U-100 syringes, available in 30-unit, 50-unit and 100-unit sizes. Treating a 50-unit barrel as 50 units per mL produces a two-fold dosing error.
Is bacteriostatic water itself risky?
It is sterile water with a preservative, not an inert liquid. The Pfizer product information states it contains 0.9 percent or 1.1 percent benzyl alcohol as a bacteriostatic preservative, so 0.9 percent is common but not universal. The same label says the safe adult intravenous volume it cites, up to 30 mL, is an estimate from experimental studies in animals, not a measured human finding.
When should I talk to a doctor rather than a forum?
Before you start anything injectable, and immediately if you feel unwell after an injection, notice redness, swelling, warmth or pain at an injection site, or develop fever. A clinician can also tell you whether an FDA-approved medicine exists for what you are trying to treat. Often one does, and the people selling vials rarely mention it.
References (22 sources)
Show
Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.
